Magrolimab (Hu5F9-G4) promotes macrophage M1 polarization and is associated with enhanced autophagy in colorectal cancer
Hu5F9-G4 demonstrates potential as a therapeutic agent in CRC by promoting M2d-to-M1 macrophage polarization, suppressing tumor progression, and influencing the autophagy pathway. These findings highlight CDKN1A and MAP1LC3B as promising targets for CRC therapy.
Authors
- Jian Dong (ORCID: https://orcid.org/0000-0002-3302-4477)
- Hao Lu (ORCID: https://orcid.org/0009-0007-1038-967X)
- Jun Yang (ORCID: https://orcid.org/0000-0002-8100-6943)
- Wei Liu (ORCID: https://orcid.org/0000-0003-0948-7807)
- Wan‐Wan Lin (ORCID: https://orcid.org/0000-0002-3207-734X)
- Ruo Bing Chen
- Tawfik Ali Hamood Alburiahi (ORCID: https://orcid.org/0009-0002-2260-9549)
Institutions
- Kunming Medical University (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1016/j.tranon.2025.102598
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00